Original from: Fujirebio
Fujirebio, a leading innovator in in-vitro diagnostics, today announced a collaboration with Stanford Medicine (Location: Palo Alto, California, USA) to advance research and innovation in the field of infectious disease testing. This collaboration aims to accelerate the adoption of ultrasensitive immunoassays that incorporate single-molecule counting technology developed by Fujirebio¡¯s Silicon Valley wholly-owned subsidiary, Fluxus, Inc. Greater test sensitivity can better inform treatment decisions in the clinic, as well as accelerate studies towards therapeutics and preventive strategies against infectious disease threats worldwide.
¡°Infectious diseases remain one of the greatest global health challenges of our time,¡± says Goki Ishikawa, President and CEO of Fujirebio Holdings, Inc. ¡°By working with the Stanford Clinical Virology Laboratory under the direction of Professor Benjamin Pinsky and the Stanford Clinical Microbiology Laboratory under the direction of Professor Niaz Banaei, we are bringing together world-class scientific expertise, cutting-edge technology, and global health insights. This collaboration underscores our shared vision to create a healthier, more resilient world.¡±
¡°This collaboration represents a significant step forward in our mission to improve public health globally, by combining Fujirebio¡¯s global IVD expertise and Fluxus¡¯ ultrasensitive detection systems with Stanford¡¯s world-renowned research,¡± says Dr. Peter Wagner, President and CEO of Fluxus, Inc. ¡°We are thrilled to be working with Stanford University¡¯s prestigious infectious disease experts.¡±
